reports
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, ...
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that in Rzeszów, Poland has completed its 500th ® Procedure. The MRI-guided therapy pro...
Profound Medical Announces Upcoming Investor Events
Profound Medical Announces Upcoming Investor Events TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February. Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4th-5th in Scottsdale, AZ.BTIG 13th Annual MedTech, Digital Health, Life Science & ...
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, ...
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO® Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased ...
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that its installed base stood at 78 as of December 31, 2025 — higher than its goal of 75 installs by the end of 2025. Profound’s TULSA-PRO qualified...
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using...
Profound Medical Corp. Announces Closing of Private Placement
Profound Medical Corp. Announces Closing of Private Placement TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”). Pursuant to the Offering, the Company issued an aggregate of 921,428 common shares at a price of US$7.00 per common share, for aggregate gross proceeds of approximately US$6.45 million. The common shares sold pursuant to the Offering are subject to a hold period of f...
Profound Medical Corp: 1 director
A director at Profound Medical Corp bought 13,908 shares at 7.186USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Profound Medical Corp. Announces Upsize of Private Placement
Profound Medical Corp. Announces Upsize of Private Placement TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor. The Company will now raise gross proceeds of up to US$6.45 million in the Offering, through the issuance of up to 921,428 common shares at a price of US$7.00 per common share. The common shares sold purs...
Profound Medical Corp. Closes $36 Million Registered Direct Offering; ...
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct offering of 5,142,870 common shares at a purchase price of $7.00 per share, for gross proceeds of approximately $36 million before fees and expenses. The ...
Profound Medical Corp. Announces Pricing of up to $40 Million Financin...
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common sha...
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Awar...
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation – CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Pejman Ghanouni, MD, P...
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PR...
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today the upcoming launch of its TULSA-AI® Volume Reduc...
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA ...
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that The Hong Center Scottsdale, led by Dr. Y. Mark...
Profound Medical Reports Strong Third Quarter 2025 Financial Results
Profound Medical Reports Strong Third Quarter 2025 Financial Results TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAA...
Profound Medical Announces Strategic Distribution Agreement with Getz ...
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO® system with Getz Healthcare, a leading distributor of medical devices, equipment and consumables, in Austra...
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® ...
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia Agreement creates runway for Profound’s incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East All required regulatory approvals to import and sell Profound’s two advanced ablative technologies in Saudi Arabia are already in place TORONTO and RIYADH, Saudi Arabia, Nov. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stag...
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® ...
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO® in Canada from Knight Therapeutics Inc. (“Knight”). The , performed using the TULSA-PRO system, is used by physicians to ablate prosta...
Profound Medical Congratulates the Busch Center for Achieving 500th TU...
Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone Clinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering precision treatment and better patient outcomes TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today unveiled new, real-world data from the international...
Profound Medical to Participate in the Stifel 2025 Healthcare Conferen...
Profound Medical to Participate in the Stifel 2025 Healthcare Conference TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 1:20 p.m. Eastern Time in NYC. The presentation will be broadcast live and archived on the Company's website at ...
Profound Medical Achieves Record Preliminary Unaudited Revenue for the...
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter To release full third quarter 2025 financial results on November 13th; conference call to follow TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the third quarter of 2025. Unless specified otherwise, all amounts in this press release are expressed...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.